Background: We present a pooled analysis of predictive and prognostic values of circulating tumour cells (CTC) and circulating endothelial cells (CEC) in two prospective trials of patients with inflammatory breast cancer (IBC) treated with neoadjuvant chemotherapy combined with neoadjuvant and adjuvant bevacizumab.
Introduction
Inflammatory breast cancer is a highly aggressive form of locally advanced breast cancer representing up to 5% of breast cancers [1] . It is characterized by high vascularity and increased microvessel density. The 5-year survival is 40% [1] . Bevacizumab, monoclonal antibody targeting VEGF, significantly improves progression-free survival and response rate in patients with advanced breast cancer but not overall survival (OS) [2] . In the neoadjuvant setting of non-IBC, bevacizumab increases tumour response rate, but its impact on survival remains unclear [3, 4] .
Circulating tumour cell (CTC) count is an independent prognostic factor in early breast cancer [5] . In the REMAGUS 02 study in patients receiving neoadjuvant chemotherapy, 23% of patients had 1 CTC/7.5 ml [6] . A similar rate (22%) was reported in the GeparQuattro trial [7] . Higher incidence of 35-54% of CTC has been reported in nonmetastatic IBC [8, 9] . We have recently reported that CTC detection is an independent prognostic factor in 52 primary HER2-positive IBC [10] . Prognostic value of circulating endothelial cells (CEC) and their potential in predicting the efficacy of anti-angiogenic therapy remains debated.
The BEVERLY-1 and -2 studies were evaluating neoadjuvant and adjuvant bevacizumab in combination with sequential neoadjuvant chemotherapy in patients with HER2-negative and HER2-positive IBC (T4d), respectively [8, 11] . An ancillary study was evaluating CTCs and CECs as candidate biomarkers. We present here an analysis of CTC and CEC clinical impact in these two pooled prospective trials including 152 patients.
Methods

Study design and participants
Full details of the BEVERLY-1 and BEVERLY-2 studies design, inclusion criteria and patient characteristics have been published previously [8, 11] . In summary, women enrolled had histologically confirmed IBC and were aged 18 years. Each trial was a single-arm, open-label, multicentre, nonrandomized, Simon (twostage) trial. All patients in Beverly 2 trial had a centrally reviewed HER-2 positive tumour . Patients in BEVERLY 1 study had HER2-negative tumour. The ER/PR status was defined by local pathologists by IHC (hormone receptor-positive if ER and/or PR 10%). Those patients with evidence of metastatic disease, a history of relapsing cancer within 5 years of entry into the study, tumoral skin permeation, or in situ contralateral breast carcinoma were excluded.
All enrolled patients provided written informed consent prior to screening procedures and for the translational research studies. 
Treatment
The treatment included four planned steps (supplementary Figure S1 , available at Annals of Oncology online). During step 1, patients received four three-weekly cycles of neoadjuvant treatment with intravenous fluorouracil (500 mg/m 2 ), epirubicin (100 mg/m 2 ), cyclophosphamide (500 mg/m 2 ), and bevacizumab (15 mg/kg), followed by four cycles of docetaxel (100 mg/ m 2 ) and bevacizumab (15 mg/kg). All treatments were given on Day 1 of the cycle.
Step 2 consisted of mastectomy and axillary lymph node dissection surgery. Bevacizumab was stopped 4 weeks prior to surgery and resumed for a further 30 weeks (10 cycles) once the wound was healed entirely. In BEVERLY-2 trial, trastuzumab was associated to docetaxel every 3 weeks from cycle 5. Patients continued receiving trastuzumab maintenance for another 42 weeks following surgery. In step 3, patients received 4-6 weeks adjuvant radiotherapy according to standard practice in combination with bevacizumab every 3 weeks. Patients with hormone receptor-positive tumours received adjuvant endocrine therapy. The final step (step 4) consisted of a 5-year follow-up after the last patient inclusion.
CTC and CEC analysis
CTC and CEC counts were measured in 7.5 and 4 ml of blood using CellSearch System (Janssen Diagnostics) which combines EpCAM immunomagnetic selection followed by anti-cytokeratin staining for CTC detection, and CD146 immunomagnetic selection and CD105 staining for CEC. Blood samples were taken from each patient: (i) before the first cycle (baseline); (ii) before the first docetaxel cycle (cycle 5); (iii) before surgery; and (iv) after surgery before the reintroduction of bevacizumab.
Endpoints and statistical analysis
Efficacy during the neoadjuvant phase was assessed by the pathological complete response (pCR) defined using Sataloff criteria as described previously [8] . pCR was defined as a total or near total treatment effect with loss of nodal involvement (Sataloff classification TA and NA or NB). Patients who did not undergo surgery, or who had insufficient tissue for assessment were regarded as a failure (no pCR).
Long-term efficacy outcomes were disease-free survival (DFS) and OS. DFS was defined as time from first neoadjuvant treatment administration until local recurrence, regional recurrence, distant recurrence, controlateral breast cancer, second primary cancer (other than squamous or basal cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, colon carcinoma in situ, or lobular carcinoma in situ of the breast) or death from any cause. OS was defined using death from any cause.
The statistical analyses were carried out using SAS version 9.3 (SAS Institute, Cary, NC). Baseline patient and disease characteristics were summarized using descriptive statistics, which are based on the frequencies and percentages for categorical variables and on the mean (SD), median and range for continuous variables. Categorical data were compared using a chisquared test and continuing data through a Wilcoxon test. Probabilities of DFS and OS were calculated using the Kaplan-Meier method and univariate associations between baseline patients were evaluated with the log-rank test. Multivariable Cox proportional hazards regression was used to evaluate the relationship between CTC, CEC and others prognostic factors. P values inferior or equal to 0.05 were considered as significant.
Results
Between October 2008 and September 2010, 152 patients were included in both trials in 21 French centres. In BEVERLY-1, 101 patients with HER2-negative IBC were enrolled. One patient was excluded from ITT analysis because of consent withdraw before starting treatment. One patient with HER2-positive tumour was wrongly enrolled in BEVERLY-1, but remains included in the analysis. In BEVERLY-2, 52 patients with HER2-positive IBC were enrolled (Table 1) . Median age was 49 years (range ), 87 (57%) patients were SBR grade III, and 64 (42%) had hormone receptor-positive tumours.
At baseline, 132 patients were both evaluable for CTC and CEC (141 for CTC and 136 for CEC). No correlation was observed between baseline CTC and CEC counts. Before the start of treatment, 55 patients had 1 CTC/7.5 ml (39%). Median CTC count for positive cases was 3.5 (range ). There was no correlation between CTC detection and baseline patients' characteristics. After four cycles of chemotherapy, a dramatic drop of CTC to a 9% positivity rate was observed (11/127) (P < 0.001) ( Figure  1A ). CTC level then remained stable and low, before surgery (9% (10/106)) and after surgery (6% (6/100)). CTC results at each time point in CTC positive patients are provided in supplemen tary Table S1 , available at Annals of Oncology online. At baseline, median CEC count was 15, range . CEC levels increased during the second part of neoadjuvant treatment (docetaxel þ bevacizumab) (P < 0.001) ( Figure 1B ), then progressively decreased after surgery.
After central review, 60 out of 152 patients showed pCR (Sataloff TA, NA/NB) after neoadjuvant treatment: the pCR percentage was 40% (95% CI [31; 48]). In multivariate analysis, pCR rate was associated with absence of hormone receptors and HER2-positive status and positive clinical lymph node status (supplementary Table S2 , available at Annals of Oncology online). There was no correlation between pCR and CTC at baseline (P ¼ 0.31) or CTC decrease (P ¼ 0.37). In BEVERLY-2 trial, a CEC count of <20 CEC/4 ml before cycle 5 was associated with increased pCR (P ¼ 0.006) [8] . By contrast, in BEVERLY-1, a positive correlation existed between the pCR rate and the CEC status before the fifth neoadjuvant cycle (pre-C5): 13 out of 39 (Figure 2A and B) . The multivariate Cox model incorporated variables known in the literature as prognostic factors (age, clinical N, histological type, SBR grade, triple negative status (hormone receptor-negative, HER2-negative) and the two variables of interest with a P value <0.05 in univariate, CTC at baseline and pCR. Triple negative status, no pCR and baseline CTC status were found to be independent prognostic factors for shorter DFS and OS (Table 2 ). Using previously reported thresholds [8] , no impact of CEC count on DFS or OS was observed in univariate analysis.
In an exploratory analysis, we sought to define a subgroup with excellent prognosis by combining CTC at baseline with pCR. Three-year DFS was longer in patients with a pCR compared with those who did not achieve pCR (74% (95% CI: [55, 86] versus 46% (95% CI: [35,56]), respectively). As shown in Figure 2C , those patients with no baseline CTC and a pCR had an excellent prognosis (3-year DFS was 88% (95% CI: [61,97]), while those with baseline CTC 1/7.5 ml and no pCR were at a high risk of relapse (3-year DFS was 34% (95% CI: [19, 49] P < 0.01). For OS ( Figure 2D ), these rates were 94% (95% CI: [63,99]) and 48% (95% CI: [31,63]) (P < 0.01), respectively. Despite a very low detection rate (between 9% and 6%) at each of the other time-points, CTC 1/7.5 ml were correlated with poor DFS and OS (Table 3) . Patients with positive CTC at baseline and still positive at any other point during follow-up, had a poorer prognosis compared to patients positive at baseline who became negative during follow-up.
Discussion
To our knowledge, this is the largest pooled analysis of prospective studies in nonmetastatic IBC evaluating CTC detection. The 39% detection rate of CTC at baseline is clearly higher than the 20.2% detection rate recently reported in a pooled analysis of individual data from 3173 patients with nonmetastatic breast cancer (Stages I-III) [5] . It does not support the preliminary hypothesis based on indirect findings that fewer CTCs may be present in IBC than in other early breast cancers. The same team has later confirmed that the proportion of patients with 1 CTC was lower among patients with stage III IBC than among patients with stage IV IBC (54.5% versus 84.3%; P ¼ 0.0002) in a retrospective study including 77 stage III and 70 stage IV patients treated with neoadjuvant therapy or first-line chemotherapy .
CTC detection at baseline, before neoadjuvant treatment, was a strong prognostic factor. Monitoring CTC level during treatment could also have been a tool to predict response. We observed a dramatic decline in CTC count after four cycles of chemotherapy combined with bevacizumab, which was prolonged before and after surgery. It has been recently reported in a prospective study of CTCs from 63 stage III IBC patients treated with neoadjuvant chemotherapy that CTC identification after primary systemic chemotherapy (positive in 27% of patients) was not associated with tumour characteristics, lymph node positivity, or pCR to systemic therapy [12] . Only two factors present after neoadjuvant chemotherapy, achievement of a pCR and presence of CTCs after neoadjuvant chemotherapy, predicted relapse. In our study, CTC detection after neoadjuvant chemotherapy was <10%. This clear drop in CTC number was not correlated to tumour response to bevacizumab-combined neoadjuvant chemotherapy. Detection of residual CTC after neoadjuvant systemic therapy and after surgery in our study was still a prognostic factor despite this very low incidence. This [12] suggests a specific impact of bevacizumab on CTCs. This is consistent with observations from the ATHENA [13] and the IC 2006-04 [14] trials in the metastatic setting and the Geparquinto trial in the neoadjuvant setting [15] . It has been suggested that by generating intra-tumoral hypoxia in human breast cancer xenografts, bevacizumab could increase the population of cancer stem cells in the tumour, thus limiting the effectiveness of antiangiogenic agents [16] . Stemness features in CTC are associated with modified phenotype such as epithelial-mesenchymal transition (EMT) [17] . The loss of epithelial marker expression in CTC which undergo EMT could explain a decrease in the detection rate during treatment with the EpCAM-based immunoselection method we used in this study. The lack of predictive value of CTC count in metastatic colorectal cancer patients treated with bevacizumab has been reported [18] . It had been also hypothesized that bevacizumab could prevent CellSearch from capturing CTCs through alteration of EpCAM isoforms expression [19] . However, even at low incidence, due to treatment or EMT, detectable CTCs during treatment remain of prognostic value. Baseline CEC levels and their increase before the introduction of trastuzumab at cycle 5 were similar to those observed in metastatic breast cancer patients treated with a similar regimen (chemotherapy and bevacizumab) in ATHENA [13] . The present pooled analysis did not confirm any trend between CEC level or variations and prediction of response or outcome. . We did not look with this CellSearch technique at a specific subpopulation of interest in CEC like Circulating Endothelial Progenitor (CEP) which could be more prognostic and requires another technique for enumeration. Predictive markers of response to antiangiogenic agent are still clearly needed.
The pCR reflects tumour sensitivity to treatment and is correlated with improved OS [4] . However not all patients with pCR are cured. CTCs reflect early tumoral dissemination. Could CTC detection identify pCR patients still at risk of relapse? At least a dozen of studies has been published concerning the evaluation of CTC in the neoadjuvant setting including IBC [20] . None has showed an association between CTC detection and the completion of a pCR, while most of the currently used clinico-pathological prognostic factors are related to tumour proliferation and associated with pCR rates. Correlation between CTC changes from baseline to each of the other time-point and DFS and OS.
However, the generalizability of our results is hampered by the use of bevacizumab in this study that it is not part of the standard of care neoadjuvant regimen. An international meta-analysis of CTC in the neoadjuvant setting in breast cancer patients is currently ongoing ('IMENEO' study). The prognostic additional information provided by CTC status might be useful for designing clinical trials focused on patients at high risk of relapse who might benefit from additional adjuvant therapies. PD-L1 is frequently expressed in IBC [21] and on CTC [22] . This could justify for example a proposal of post-neoadjuvant immunetherapy in patients with absence of pCR and/or presence of CTC at baseline.
In conclusion, detection rate of CTC at baseline in IBC was 39% with a strong and independent prognostic value for DFS and OS. Combination of pCR after neoadjuvant treatment with CTC at baseline defines subgroups of IBC with excellent DFS (88% at 3 years) in case of pCR and negative CTC rate or very dismal outcome (34% at 3 years) in case of absence of pCR and positive CTC rate. This observation suggests that the therapeutic response cannot totally revert the poor prognosis associated to the presence of CTC, indicator of micrometastases. We suggest that CTC count at baseline could be part of IBC stratification in future prospective trials.
